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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, which rapidly
leads to chronic respiratory failure requiring mechanical ventilation. Currently, forced vital capacity
(FVC) < 50% is considered as physiologic marker for admitting patients to Noninvasive Positive
Pressure Ventilation (NPPV) intervention, although it has been recently shown the median survival
of patients with baseline FVC < 75% much shorter than median survival of patients with baseline
FVC > 75%, independently by any treatment.
Aim: To assess the role of NPPV in improving outcome of ALS, a retrospective analysis was
performed to investigate 1 year survival of ALS patients with FVC < 75% and nocturnal respiratory
insufficiency, treated with NPPV, compared to a well-matched population of ALS patients, who
refused or was intolerant to NPPV.
Methods: We investigated seventy-two consecutive ALS patients who underwent pulmonary
function test. Forty-four presented a FVC > 75% and served as control group. Twenty-eight
patients presented a FVC < 75% and showed, at polysomnography analysis, nocturnal respiratory
insufficiency, requiring NPPV; sixteen were treated with NPPV, while twelve refused or were
intolerant.
Results: Increased survival rate at 1 year in patients with FVC < 75% treated with NPPV, as
compared to those who refused or could not tolerate NPPV (p = 0.02), was observed. The median
rate of decline in FVC% was slower in NPPV patients than in patients who did not use NPPV (95%
CI: 0.72 to 1.85; p < 0.0001).
Conclusion: This report demonstrates that early treatment with NPPV prolongs survival and
reduces decline of FVC% in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by progressive neuromuscular atro-
phy with early involvement of respiratory system, rapidly
leading to pulmonary collapse, which requires mechani-
cal ventilation and represents the major cause of mortality
[1]. Over the last decade, noninvasive positive pressure
ventilation (NPPV) has been indicated and widely recom-
mended in ALS patients with chronic respiratory failure
[2], since not only reduces dyspnoea and improves per-
sistent hypoventilation, [3] but may also extend life of
individuals affected by this fatal disease [2,4]. Few
patients receive NPPV, although early prediction of respi-
ratory muscle involvement might be useful to plan
mechanical ventilation interventions before chronic respi-
ratory failure occurs [5]. Currently, forced vital capacity
(FVC) is considered as physiologic marker to admit ALS
patients to NPPV treatment [6]. According to previous
studies, NPPV should be offered to all subjects with a FVC
of less than 50% [7,8]. Recently reports have shown the
ultimate role of FVC in ALS patients: a study disclosed that
chronic respiratory failure might initiate within 1 year
from the first presentation of ALS, in a great proportion of
patients, independently of their first respiratory func-
tional status (median FVC% 87) [9], suggesting that the
progressive decline of respiratory function might be due
to a sudden weakness of respiratory muscles. By the con-
trast, in a large cohort observation of 1034 patients with
ALS, the median survival of patients with baseline FVC <
75% was much shorter than the median survival of
patients with baseline FVC > 75% [10], independently by
the medical treatment, indicating that a single FVC value
is a predictor of survival and disease progression.
Interestingly, neuromuscular deterioration and respira-
tory decline are also involved in severe sleep-disordered
breathing [11] which occurs at an early stage of ALS [12].
Polysomnography analysis reveals impaired nightly sleep
hypoventilation, increasing nocturnal oxygen desatura-
tion index, high frequency of apnoea/hypopnea events
[13], resulting in nocturnal respiratory insufficiency and
decline of cognitive function [14]. Recent studies demon-
strated that noninvasive positive pressure ventilation,
decreasing sleep-disordered breathing, improves quality
of life of patients with ALS [15,16]. These substantiate
data address the hypothesis that sleep disturbance
together with the impairment of the respiratory functional
status are the earliest indication of respiratory insuffi-
ciency in ALS patients [17]. In our experience, all patients
with FVC < 75% showed nocturnal respiratory disorders.
Aim of the present study was to assess the role of early
NPPV treatment in improving outcome of ALS patients. A
retrospective analysis was performed to investigate 1 year
survival of ALS patients with FVC < 75% and nocturnal
respiratory insufficiency, who were treated with NPPV,
compared to a well-matched group of ALS patients who
did refuse or was intolerant to NPPV.
Methods
Study design and population
We investigated seventy-two (43 males) consecutive
patients (mean symptom duration at diagnosis was 16.2
± 5.3 months) who were referred to the pulmonary func-
tion and polysomnography laboratories at University of
Bari and Catania, from July 2003 to January 2008.
Patients were eligible for the analysis if their ages were
between 18 and 80 years, had definite or probable diagno-
sis of ALS. Patients who had other neurological disease, or
lung disease unrelated to ALS, were excluded. The proto-
col was accepted by the local Institutional Review Board.
Patients were divided into three groups: forty-four
patients (27 males) showed a FVC > 75%, did not
undergo polysomnography test, and served as control
group (group 1). Twenty-eight patients (16 males) pre-
sented a FVC < 75% and nocturnal respiratory insuffi-
ciency at polysomnography, requiring NPPV. Sixteen were
treated with NPPV (group 2), while twelve refused or were
intolerant to NPPV (group 3). Table 1 shows the demo-
graphic features and measures of disease severity of the
three groups of patients.
Amyotrophic Lateral Sclerosis Functional Rating Scale 
(ALSFRS) and revised ALSFRS (ALSFRS-R)
Disease severity of the patients with FVC < 75% (groups 2
and 3) was measured using the Revised-Amyotrophic Lat-
eral Sclerosis Functional Rating Scale (ALSFRS-R) (Table
1) [18]. ALSFRS is a 10-item functional inventory which
was devised for use in therapeutic trials in ALS [19]. Each
item is rated on a 0–4 scale, inversely related to disease
severity, by the patient and/or caregiver. The ALSFRS
assesses patients' levels of self-sufficiency in areas of feed-
ing, grooming, ambulation and communication. The
revised ALSFRS-R, ultimately, incorporates three addi-
tional assessments including dyspnea, orthopnea, and the
need for ventilatory support [18].
Pulmonary function testing and arterial blood gas analysis
Pulmonary function tests were performed in the pulmo-
nary function laboratory of our Institutes using a spirom-
eter (PK Morgan Ltd; Gillingham, UK). The equipment
was calibrated daily using a 3-L syringe and the analysis
was performed in accordance to the guidelines of the ATS
[20]. The best of three reproducible values was expressed
as a percentage of the predicted normal value. To over-
come mouth leaks, a full-face mask was adapted for bul-
bar ALS patients. Patients unable to perform the test were
excluded from the study.
Arterial blood for the analysis of gases during room air
breathing was drawn with the patient in the supine posi-
tion, and PaO2, PaCO2 and pH were measured in a bloodOrphanet Journal of Rare Diseases 2009, 4:10 http://www.ojrd.com/content/4/1/10
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gas analyzer (Model 1312; Instrumentation Laboratory;
Milan, Italy).
Sleep study
All subjects of groups 2 and 3 were evaluated in the sleep
laboratory of the Institutes of Respiratory Diseases of the
Universities of Bari and Catania for one night. They were
monitored continuously for 8 hours using a 19-channel
polysomnograph (Compumedic; Sydney, Australia).
Polysomnography was performed after one night of adap-
tation in the hospital, according to standard methods[21].
Polysomnography consisted of continuous polygraphic
recording from surface leads for electroencephalogram,
electro-oculography, electromyography, electrocardio-
gram, thermistors for nasal and oral airflow, thoracic and
abdominal impedance belts for respiratory effort, pulse
oximetry for oxyhemoglobin level, and sensor for the
position during sleep. Apnoea was defined as complete
cessation of airflow lasting ≥ 10 seconds; hypopnea was
defined as either a ≥ 50% reduction in airflow for ≥ 10 sec-
onds or a < 50% but discernible reduction in airflow
accompanied either by a decrease in oxyhemoglobin satu-
ration of > 4% or an arousal. Severity of nocturnal respira-
tory insufficiency was assessed by the apnoea-hypopnea
index (AHI), mean total sleeping time, and mean arterial
oxygen saturation (SpO2). Table 2 shows the polysomno-
graphic analysis of the groups 2 and 3.
Noninvasive ventilation
Patients were prescribed NPPV per standard guidelines,
when FVC was less than 75% and nocturnal respiratory
symptoms were present. Pressures were routinely begun at
8 cmH2O IPAP and 3 cmH2O EPAP [22]. The devices used
were a volume-controlled ventilator (Life Care Products,
Lafayette, Colorado) in assist-control mode or bilevel pos-
itive-pressure device (BiPAP, Respironics, Inc., Murrys-
ville, Pennsylvania) in spontaneous-timed mode. Tidal
volume (for the volume-controlled ventilator) or pressure
(for the bilevel positive-pressure device) were initially
adjusted for chest rise, leaks, and patient comfort and
were adjusted on subsequent visits to control hypercapnia
and dyspnea. Patients were instructed to use noninvasive
positive-pressure ventilation nightly as tolerated and as
necessary in the daytime, according to previous reports
[2,23]. Tolerance was defined as the ability to sleep
nightly while receiving noninvasive positive-pressure ven-
tilation for at least 4 consecutive hours.
Statistical analysis
Data are presented as means ± standard deviation (SD).
Unpaired student t-test was used for comparisons
between patients treated with NPPV and those who were
intolerant or declined NPPV. Survival comparisons were
performed by Mantel-Haenszel log-rank test. Pearson cor-
relation coefficients were used to assess the association
Table 1: Baseline Characteristics of Patients Entering the Study
FVC > 75% FVC < 75% p-value between groups 2–3
Group 1 Group 2 (NPPV) Group3 (not vent)
N4 4 1 6 1 2
male/female 27/17 9/7 7/5
Age 51.16 (7.39) 55.93 (5.09) 57.54 (6.54) ns
BMI 22.72 (3.90) 21.98 (4.48) 22.85 (3.16) ns
Bulbar onset 13/44 5/16 4/12 ns
Spinal onset 23/44 8/16 6/12 ns
FVC% 83.3 (11.84) 65.13 (13.37) 62.35 (12.75) ns
FEV1% 88.12 (13.98) 64.53 (14.17) 61.6 (13.8) ns
PaO2 mmHg 90.35 (9.58) 79.91 (12.48) 77.35 (8.54) ns
PaCO2 mmHg 36.43 (6.72) 41.83 (9.27) 39.48 (8.92) ns
ALSFRS-R 28.7 (6.1) 26.7 (7.1) ns
Data are presented as mean (± SD); ns = not significant
Table 2: Polysomnographic features of the groups 2 (FVC < 75% with NPPV) and 3 (FVC < 75% without NPPV)
FVC < 75% Group 2 (16) (NPPV) Group 3 (12) (no NPPV) p-value
SpO2 per min, (% ± SD) 89 ± 5.2 88 ± 7.4 ns
Total sleep time, min, (mean ± SD) 312 ± 54 306 ± 62 ns
AHI median (range ± SD) 12 ± 7 11 ± 8 ns
AI/h 7 ± 1,38 3.8 ± 6,5 ns
HI/h 17 ± 5,61 19 ± 1.5 ns
Data are presented as mean (± SD); ns = not significantOrphanet Journal of Rare Diseases 2009, 4:10 http://www.ojrd.com/content/4/1/10
Page 4 of 7
(page number not for citation purposes)
between the different parameters (Prism vers. 4.0 for Win-
dows). An unpaired t-test was used for comparisons
between groups for FVC% decline. Significance was estab-
lished at a p-value < 0.05.
Results
The mean (SD) age at disease onset in our patient popula-
tion was 54.9 (6.3) years. As shown in Table 1, there were
no statistical significant differences between the groups 2
and 3 of ALS patients regarding sex, age, Body Mass Index
(BMI), time from diagnosis, bulbar or spinal onset
involvement, FVC%, FEV1%, PaO2, PaCO2, ALSFRS-R
questionnaire score and riluzole treatment. No statistical
significant differences were observed at polysomnography
test in terms of saturation% per minute, total sleep time,
and AHI between the group 2 and 3 of patients (Table 2).
In Figure 1 is shown the 1 year survival slopes of the
groups of ALS patients with FVC > 75%, and of patients
with FVC < 75% treated or not with NPPV. Kaplan-Meier
1 year survival rates showed a statistical significant differ-
ence between ALS patients with FVC < 75% treated with
NPPV and ALS patients with FVC < 75% who refused or
were intolerant to NPPV (12/16 vs. 4/12; χ2 = 5.32; p =
0.02), while not statistical significant difference was
found between patients with FVC > 75% vs. patients with
FVC < 75% treated with NPPV (37/44 vs 12/16; χ2 =
0.408; p = 0.5). Table 3 shows the causes of death of ALS
patients with FVC < 75%. Among survivors patients with
FVC < 75%, the median rate FVC decline following initia-
tion of NPPV was slower in patients who tolerated NPPV
(group 2) than in patients who did not tolerate NPPV
(group 3), (Figure 2), FVC% slope change per month was
(1.52 ± 0.3) in group 2 and 2.81 ± 0.8 in group 3 (p <
0.0001).
Discussion
The development of early progressive hypoventilation
affects the natural history of ALS, and time for admitting
patients to NPPV represents a crucial dilemma for neurol-
Kaplan-Meier plots of survival in 72 patients affected by amyotrophic lateral sclerosis (ALS) from the initiation of NPPV Figure 1
Kaplan-Meier plots of survival in 72 patients affected by amyotrophic lateral sclerosis (ALS) from the initiation 
of NPPV. (Black circle) = 44 patients with ALS with FVC > 75%, (Black triangle) = 16 patients with ALS with FVC < 75% 
treated with NPPV, (Black square) = 12 patients with ALS with FVC < 75% not treated with NPPV. ALS patients with FVC < 
75% treated with NPPV vs. patients with ALS with FVC < 75% intolerant to NPPV: χ2 5.32; *p = 0.02. Patients with ALS with 
FVC > 75% vs. patients with ALS with FVC < 75% treated with NPPV: χ2 = 0.408 p = 0.5. Patients with ALS with FVC > 75% vs. 
patients with ALS with FVC < 75% not treated with NPPV: χ2 = 15.4; p < 0.0001.Orphanet Journal of Rare Diseases 2009, 4:10 http://www.ojrd.com/content/4/1/10
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ogists and pulmonologists. The use of noninvasive posi-
tive pressure ventilation has yet been demonstrated to
improve survival in ALS patients [2,4,23], although the
most useful indicator of chronic respiratory decline and
dead risk was previously considered a baseline FVC < 50%
[6-8]. Our findings show that ALS patients who receive
noninvasive positive pressure ventilation when Forced
Vital Capacity at baseline is less than 75% have a signifi-
cant survival improvement at 1 year, as compared to
those, with similar FVC, who refused or can not tolerate
NPPV (p = 0.02). In addition, the median rate of FVC
decline was slower in survived patients who tolerated
NPPV than in patients who were intolerant to NPPV (p <
0.0001). These results are independent by differences in
sex, age, BMI, bulbar or spinal onset, pulmonary func-
tions, arterial blood gas analysis, ALSFRS-R questionnaire
score, riluzole treatment, and polysomnographic charac-
teristics, including saturation % per minute, total sleep
time, and AHI. Recent papers showed contrasting data
about disease progression and survival indicators in
patients with ALS. While a study established that chronic
hypoventilation requiring mechanical ventilation can rap-
idly occur, in a small number of patients, independently
of their initial respiratory function degree (median FVC%
87) [9], a recent paper revealed the FVC value > 75%, as
an early positive predictor of survival in a large number
(1034) of ALS patients[10]. Very lately, in a randomised
controlled trial, Bourke and co-workers showed that
application of noninvasive ventilation when orthopnea
occurred, associated to reduction of maximal inspiratory
pressure < 60% of the predicted, improved survival, as
compared to standard care, in ALS patients [24]. Our data,
already published as preliminary results [25], are similar
to the findings of Lechtzin and colleagues, who admitted
Slope of FVC% in 1 year between survivors of the groups 2 and 3 Figure 2
Slope of FVC% in 1 year between survivors of the groups 2 and 3. Blue line: Group 2 (12) (NPPV); Red line: Group 3 
(4) (no NPPV). X axis: months, Y axis: FVC%. FVC% slope change per month in group 2 (1.52 ± 0.3) and group 3 (2.81 ± 0.8); 
p < 0.0001.Orphanet Journal of Rare Diseases 2009, 4:10 http://www.ojrd.com/content/4/1/10
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ALS patients with FVC < 65% to mechanical ventilation
and observed a significant prolongation of survival [26].
Our study provides additional data about the role of sleep
disorders, which actively participate to respiratory failure
in ALS. Indeed, the respiratory failure may be present in
the absence of breathlessness at rest, or orthopnoea [27],
while, it has been observed that sleep disturbance appears
at an early stage of disease [12], when respiratory muscle
weakness is not sufficient to cause daytime orthopnea.
Sleep-disordered breathing might be likely the earliest
indication of respiratory insufficiency [17]. In addition, in
ALS patients with nocturnal insufficiency, NPPV has been
demonstrated to correct sleep-disordered breathing,
enhancing quality of life[16].
This study supports the hypothesis that NPPV should be
immediately prescribed to ALS patients with mild respira-
tory dysfunction (FVC < 75%) and polysomnographic
signs of nocturnal hypoventilation, for at least 4 hours per
day, in order to delay the rapid progression toward
chronic respiratory failure. In particular, NPPV treatment
significantly decreased the mortality rate of ALS patients
with FVC < 75%, as well as the median FVC% rate decline,
resulting much slower when compared to the slope of
vital capacity of ALS patients with FVC < 50%, treated with
4 hours per day with bi-level intermittent positive pres-
sure, as earlier reported [23].
Although in the present study, the small number of
patients treated with noninvasive mechanical ventilation
can not give significance for a definitive conclusion, our
findings encourage the early use of NPPV, in order to
extend survival and to reduce the decline of lung volumes
and compliance, thus ameliorating the respiratory func-
tion and quality of life of these patients.
In conclusion, this preliminary report demonstrates that
early treatment with NPPV prolongs survival in ALS
patients, indicating for the first time that NPPV should be
introduced when FVC drops below 75% and not 50%, as
considered standard care for these patients previously,
although further multicentric studies must be conducted
to well establish it.
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